the concerted action on the antigenicity of rDNA derived pharmaceuticals
First Statement of Responsibility
edited by Huub Schellekens.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Dordrecht
Name of Publisher, Distributor, etc.
Springer Netherlands : Imprint : Springer
Date of Publication, Distribution, etc.
1997
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
(112 pages)
CONTENTS NOTE
Text of Note
The Incidence and Clinical Significance of Antibodies to Interferon-g in Patients with Solid Tumors; K. Oberg. Interferon Antibodies in Patients with Infectious Diseases; G. Antonelli, et al. Treatment-Induced Antibodies to Interleukin-2; O. Prummer. Natural Antibodies to IL-2; A. Balsari, et al. Natural Antibodies to Interferon-Gamma; A. Caruso, et al. Anti-Cytokine Autoantibodies: Epiphenomenon or Critical Modulators of Cytokine Action; P.H. van der Meide, et al. Potential Therapeutic Use of Antibodies Directed Toward HuIFN-g; G. Froyen, et al. Structure Activity of Type I Interferons; G. Viscomi. Measurement of Cytokine Antibodies. Test Development; M. Svenson, et al. The Expression of Potency of Neutralizing Antibodies for Interferons and Other Cytokines; S.E. Grossberg, et al.
SUMMARY OR ABSTRACT
Text of Note
This book, written by leading authors in the field, is the first to deal with all aspects of cytokine antibodies, from test methodology and standardization to biological consequences and functions. It encompasses antibodies induced by cytokines used therapeutically and antiviral antibodies. To understand the biology, the effects of cytokine antibodies in experimental animal models and patients are also discussed. The book is intended for researchers of cytokine biology, pharmaceutical companies developing cytokines and cytokine antibodies as therapies, and clinicians interested in modulating the immune system as therapy.